Home›Companies›Biotech & Pharma›ParcelBio

Parcel Biosciences, Inc.

ParcelBio develops mRNA medicines for people with autoimmune disease and cancer.

Updated Nov 11, 2026·Latest SEC filing Mar 4, 2026·Suggest an edit

About ParcelBio

ParcelBio is a private company based in San Francisco, California, incorporated in 2024 in Delaware. It has reported $13,174,977 raised in one offering on Form D since March 2026. Its chief executive is David Weinberg.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 6, 2026Mar 4, 2026$13,174,977fully sold52$253KEquityRule 506(c)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on ParcelBio's Form D filed Mar 4, 2026.

MC
Christopher Carlson
Christopher Carlson
Co-founder and CSO, director
David Weinberg
David Weinberg
Co-founder and CEO, director

Sources

  1. SECParcel Biosciences, Inc. filing history